Company: PFSA
Filing Date: 2025-08-22
Form Type: S-1/A
Source: 0001213900-25-079829
Chunk: 208

Company: Profusa, Inc.
Filing Date: 2025-08-22
Form: S-1/A
Chunk 208
---
 additional Congressional action is taken (with the exception of a temporary suspension from May 1, 2020 through March 31, 2022 and a subsequent reduction to 1% from April 1, 2022 until June 30, 2022). To offset the temporary suspension during the COVID -19pandemic, in 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second half of the year. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. We expect that these initiatives, as well as other healthcare reform measures that may be adopted in the future, as well as the trend toward managed healthcare and increasing influence of managed care organizations, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government -fundedprograms may result in a similar reduction in payments from private payors. The implementation of current and future cost containment measures or other healthcare reforms may adversely affect our operations and prevent us from being able to generate revenue, attain profitability or commercialize our product candidates. 133

MANAGEMENT Directors and Executive Officers The following table sets forth the names and ages of all of our directors and executive officers as of April 28, 2025. Our officers are appointed by, and serve at the pleasure of, the Board of Directors.

| Name                              |     | Age |     | Position                                       |
| Directors and Executive Officers: |     |     |     |                                                |
| Ben C. Hwang, Ph.D.               |     |  57 |     | Chairman of the Board; Chief Executive Officer |
| Fred Knechtel                     |     |  64 |     | Chief Financial Officer                        |
| Rajesh Asorpota                   |     |  56 |     | Director                                       |
| Lauren Chung                      |     |  48 |     | Director                                       |
| Peter O’Rourke                    |     |  52 |     | Lead Independent Director                      |
| Jack Stover                       |     |  71 |     | Director                                       |

The following is information about the experience